This story is developing….
5 – 10 unit play.
We’re initiating Cassava Sciences with a Strong Buy and a target of $250 based on discussions with our biotech contacts. Pipeline strength and we’re hearing that efficacy is off the charts. Lastly, best case scenario, $SAVA could 7x off these levels to $1,000 It joins $SURF as tied for first for our best global idea.